Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of JNJ-68284528 CAR-T vs PVd or DPd in relapsed and lenalidomide-refractory multiple myeloma
2019-001413-16Phase 3Unknown
- Sponsor
- Janssen Pharmaceutical
- Start
- Nov 2019
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Countries
- 1
01
Overview
Phase 3, randomised trial of ciltacabtagene autoleucel in multiple myeloma (MM) (3 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Progression-free survival. Status: unknown.
02
Drugs
ciltacabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2019-001413-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-001413-16.